EMAIL THIS PAGE TO A FRIEND

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin.


PMID 25595740

Abstract

Polymeric film-forming systems (FFSs) are potential drug delivery systems for topical application to the skin. The FFSs form thin and transparent polymeric films in situ upon solvent evaporation. Their application convenience and cosmetic attributes, superior to conventional semi-solids, may offer improved patient compliance. This study represents the first phase of an investigation into the use of FFSs for prolonged dermal drug delivery. FFS formulations were distinguished based on their ability to sustain the release of betamethasone 17-valerate (BMV) in vitro over 72 h. The effect of film-forming polymer (hydrophilic: hydroxypropyl cellulose (Klucel™ LF); hydrophobic: polymethacrylate copolymers (Eudragit® NE and Eudragit® RS), and polyacrylate copolymer (Dermacryl® 79) was first determined, and then the impact of incorporation of plasticisers (triethyl citrate, tributyl citrate, and dibutyl sebacate) was examined. The Klucel film released a significantly higher amount of BMV than the hydrophobic FFS, 42 versus 4 μg/cm(2), respectively. The release was increased when a plasticiser was incorporated, and with higher enhancement ratios achieved with the more lipophilic plasticisers. In conclusion, the results show that FFSs can sustain drug release (hence representing useful systems for prolonged dermal therapy) and emphasise the importance of the formulation on drug delivery, with the type of polymer being of greatest significance.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

S2875
Dibutyl sebacate, ≥90%
C18H34O4
84838
Dibutyl sebacate, Selectophore, ≥97.0%
C18H34O4
80865
Dibutyl sebacate, analytical standard
C18H34O4
PHR1216
Dibutyl sebacate, Pharmaceutical Secondary Standard; Certified Reference Material
C18H34O4
84840
Dibutyl sebacate, ≥97.0% (GC)
C18H34O4
D49504
Dibutyl sebacate, technical grade
C18H34O4
M55909
Methyl methacrylate, contains ≤30 ppm MEHQ as inhibitor, 99%
C5H8O2
W400201
Methyl methacrylate, 99%, stabilized
C5H8O2
Y0001488
Methyl methacrylate, European Pharmacopoeia (EP) Reference Standard
C5H8O2
S7670
Sodium acetate trihydrate, BioXtra, ≥99.0%
C2H3NaO2 · 3H2O
S1304
Sodium acetate trihydrate, meets USP testing specifications
C2H3NaO2 · 3H2O
71188
Sodium acetate trihydrate, BioUltra, ≥99.5% (NT)
C2H3NaO2 · 3H2O
71193
Sodium acetate trihydrate, purum p.a., ≥99.0% (NT)
C2H3NaO2 · 3H2O
25022
Sodium acetate trihydrate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E262, 99.0-101.0% (calc. to the dried substance), ≤0.00002% Al
C2H3NaO2 · 3H2O
236500
Sodium acetate trihydrate, ACS reagent, ≥99%
C2H3NaO2 · 3H2O
S8625
Sodium acetate trihydrate, ReagentPlus®, ≥99.0%
C2H3NaO2 · 3H2O
27497
Tributyl citrate, ≥97.0%
C18H32O7
PHR1154
Tributyl citrate, Pharmaceutical Secondary Standard; Certified Reference Material
C18H32O7
1680608
Tributyl citrate, United States Pharmacopeia (USP) Reference Standard
C18H32O7
14849
Triethyl citrate, analytical standard
C12H20O7
27500
Triethyl citrate, ≥98.0% (GC)
C12H20O7
W308307
Triethyl citrate, ≥99%, FCC, FG
C12H20O7
W308315
Triethyl citrate, natural, ≥97%, FG
C12H20O7
PHR1153
Triethyl citrate, Pharmaceutical Secondary Standard; Certified Reference Material
C12H20O7